JP5297202B2 - 結腸直腸癌の予後のための遺伝子発現マーカー - Google Patents

結腸直腸癌の予後のための遺伝子発現マーカー Download PDF

Info

Publication number
JP5297202B2
JP5297202B2 JP2008550454A JP2008550454A JP5297202B2 JP 5297202 B2 JP5297202 B2 JP 5297202B2 JP 2008550454 A JP2008550454 A JP 2008550454A JP 2008550454 A JP2008550454 A JP 2008550454A JP 5297202 B2 JP5297202 B2 JP 5297202B2
Authority
JP
Japan
Prior art keywords
expression
cancer
normalized
rna
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008550454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523028A5 (https=
JP2009523028A (ja
Inventor
ウェイン コーウェンズ，
ジョッフル ビー． ベイカー，
キム クラーク，
ジェームス ハケット，
ドリュー ワトソン，
スンミュン パク，
Original Assignee
ジェノミック ヘルス， インコーポレイテッド
エヌエスエービーピー ファウンデーション， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェノミック ヘルス， インコーポレイテッド, エヌエスエービーピー ファウンデーション， インコーポレイテッド filed Critical ジェノミック ヘルス， インコーポレイテッド
Publication of JP2009523028A publication Critical patent/JP2009523028A/ja
Publication of JP2009523028A5 publication Critical patent/JP2009523028A5/ja
Application granted granted Critical
Publication of JP5297202B2 publication Critical patent/JP5297202B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008550454A 2006-01-11 2007-01-11 結腸直腸癌の予後のための遺伝子発現マーカー Active JP5297202B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75839206P 2006-01-11 2006-01-11
US60/758,392 2006-01-11
US80027706P 2006-05-12 2006-05-12
US60/800,277 2006-05-12
US81007706P 2006-05-31 2006-05-31
US60/810,077 2006-05-31
PCT/US2007/000995 WO2007082099A2 (en) 2006-01-11 2007-01-11 Gene expression markers for colorectal cancer prognosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012272400A Division JP5486664B2 (ja) 2006-01-11 2012-12-13 結腸直腸癌の予後のための遺伝子発現マーカー

Publications (3)

Publication Number Publication Date
JP2009523028A JP2009523028A (ja) 2009-06-18
JP2009523028A5 JP2009523028A5 (https=) 2010-03-18
JP5297202B2 true JP5297202B2 (ja) 2013-09-25

Family

ID=38257063

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2008550454A Active JP5297202B2 (ja) 2006-01-11 2007-01-11 結腸直腸癌の予後のための遺伝子発現マーカー
JP2012272400A Active JP5486664B2 (ja) 2006-01-11 2012-12-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124950A Active JP5486719B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124949A Active JP5486718B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124952A Pending JP2013215201A (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124948A Active JP5486717B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124951A Active JP5486720B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2012272400A Active JP5486664B2 (ja) 2006-01-11 2012-12-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124950A Active JP5486719B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124949A Active JP5486718B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124952A Pending JP2013215201A (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124948A Active JP5486717B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー
JP2013124951A Active JP5486720B2 (ja) 2006-01-11 2013-06-13 結腸直腸癌の予後のための遺伝子発現マーカー

Country Status (14)

Country Link
US (10) US7695913B2 (https=)
EP (9) EP2377950B1 (https=)
JP (7) JP5297202B2 (https=)
KR (1) KR20090003178A (https=)
AU (1) AU2007204826B2 (https=)
BR (1) BRPI0706511A2 (https=)
CA (1) CA2636984A1 (https=)
DK (1) DK1974058T3 (https=)
ES (1) ES2491222T3 (https=)
IL (1) IL192794A (https=)
MX (1) MX2008008973A (https=)
NO (1) NO20083461L (https=)
NZ (7) NZ593226A (https=)
WO (1) WO2007082099A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295598B2 (en) 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US20080234946A1 (en) * 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
US20090076734A1 (en) 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
CA2681899C (en) 2007-03-27 2018-06-19 Immunovia Ab Methods for diagnosis of pancreatic adenocarcinoma, and biomarkers and arrays for use in the same
US20090123920A1 (en) * 2007-11-08 2009-05-14 Maher Albitar Jak2 mutations
ES2332167B1 (es) * 2007-12-04 2010-10-25 Universidad Autonoma De Madrid Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal.
WO2009123634A1 (en) * 2008-04-02 2009-10-08 Regents Of The University Of California Systems and methods for predicting response of biological samples
WO2009114836A1 (en) 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8273534B2 (en) 2008-05-14 2012-09-25 Genomic Health, Inc. Predictors of patient response to treatment with EGF receptor inhibitors
US20100029748A1 (en) * 2008-08-04 2010-02-04 Sloan-Kettering Institute For Cancer Research Metastasis Promoting Genes and Proteins
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
SG10201401722XA (en) * 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
SG187045A1 (en) 2010-08-13 2013-02-28 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
CA2811015A1 (en) 2010-09-15 2012-03-22 Almac Diagnostics Limited Molecular diagnostic test for cancer
JP2014509189A (ja) 2011-01-25 2014-04-17 アルマック ダイアグノスティックス リミテッド 結腸ガン遺伝子発現シグネチャーおよび使用方法
JP2014533100A (ja) * 2011-11-04 2014-12-11 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ 結腸直腸癌の分析のための方法およびバイオマーカー
MX2014006404A (es) 2011-11-28 2015-03-03 Institució Catalana De Recerca I Estudis Avançats Metodos y kits para el pronostico del cancer colorrectal.
US10519506B2 (en) 2011-12-22 2019-12-31 Baylor Research Institute Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer
AU2013208757A1 (en) 2012-01-09 2014-07-24 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
WO2013150167A2 (es) 2012-04-03 2013-10-10 Servicio Andaluz De Salud Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico
WO2014077915A1 (en) * 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
ES2475366B1 (es) * 2012-12-10 2015-05-05 Fundación Imdea Alimentación Métodos y kits para el pronóstico del cáncer colorrectal
ES2859645T3 (es) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Detección de neoplasia
US20140272963A1 (en) 2013-03-14 2014-09-18 Abbott Molecular Inc. Cell preparations and cell supports and their use in theranosis
WO2014191559A1 (en) * 2013-05-30 2014-12-04 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
US10185809B1 (en) * 2013-10-15 2019-01-22 Iqvia Inc. Patient projection methodology
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
CA2943827A1 (en) * 2014-03-28 2015-10-01 Applied Proteomics, Inc. Protein biomarker profiles for detecting colorectal tumors
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016025717A1 (en) 2014-08-14 2016-02-18 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
AU2015334841B2 (en) 2014-10-24 2022-02-03 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
US10016159B2 (en) 2014-10-24 2018-07-10 Koninklijke Philips N.V. Determination of TGF-β pathway activity using unique combination of target genes
JP7065610B6 (ja) 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
JP6072396B2 (ja) 2014-11-25 2017-02-01 三菱電機株式会社 空圧式アクチュエータ
US20180148789A1 (en) * 2014-12-01 2018-05-31 University Of Southern California Methods for treating and assessing tumor invasion and metastasis
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP6232689B2 (ja) * 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
US11450409B2 (en) 2015-08-14 2022-09-20 Innosign B.V. Determination of NFkB pathway activity using unique combination of target genes
CN108138235B (zh) 2015-08-31 2022-04-15 梅约医药教育及研究基金会 检测胃肿瘤
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
MX388345B (es) 2016-05-10 2025-03-19 Mayo Found Medical Education & Res Métodos y materiales para estadificar cáncer de piel y seleccionar tratamiento.
WO2018165532A1 (en) 2017-03-10 2018-09-13 Baylor Research Institute Methods for diagnosing and treating gastric cancer using mirna expression
WO2018224731A1 (en) * 2017-06-05 2018-12-13 Ls Cancerdiag Oy A method for determining whether a subject is at risk to develop cancer and tools related thereto
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
JP7027179B2 (ja) * 2018-01-24 2022-03-01 キヤノン株式会社 給送回転体、シート給送装置及び画像形成装置
AU2019230200A1 (en) 2018-03-08 2020-10-29 University Of Notre Dame Du Lac Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
KR102007450B1 (ko) * 2018-05-31 2019-08-05 한국과학기술연구원 대장암 치료제 발굴을 위한 신규 표적 치료 작용점의 스크리닝 방법 및 이를 이용하여 선별한 대장암 치료 예후 바이오마커
CA3107401A1 (en) 2018-07-25 2020-01-30 Skylinedx B.V. Gene signatures for predicting metastasis of melanoma and patient prognosis
US12370240B2 (en) 2018-11-28 2025-07-29 Genascence Corporation Methods and compositions for treating osteoarthritis
WO2020123699A1 (en) * 2018-12-11 2020-06-18 The Trustees Of Columbia University In The City Of New York Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof
CN110257518B (zh) * 2019-07-01 2022-08-02 复旦大学附属中山医院 一种用于预测转移性结直肠癌转化治疗疗效的基因集
US12057959B2 (en) * 2019-12-31 2024-08-06 Mcafee, Llc Device identification
KR102263984B1 (ko) * 2020-02-21 2021-06-11 재단법인 아산사회복지재단 직장암 환자에서 수술-전 화학방사선치료의 반응을 예측하기 위한 분석방법
KR102535150B1 (ko) * 2020-04-14 2023-05-23 주식회사 베르티스 암의 예후 예측용 조성물
KR20230017206A (ko) * 2020-04-29 2023-02-03 프리놈 홀딩스, 인크. 결장 세포 증식성 장애를 식별하기 위한 rna 마커 및 방법
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112322730B (zh) * 2020-10-16 2023-04-18 上海市第一人民医院 预测肿瘤耐药、复发的标志物kifc1及其抑制剂和应用
EP4026918A1 (en) 2021-01-12 2022-07-13 Koninklijke Philips N.V. Prediction of an outcome of a colorectal cancer subject
CN113667673B (zh) * 2021-07-15 2024-02-06 武汉血液中心 一种类孟买血型FUT1 236delG等位基因及其检测方法和应用
KR20230059642A (ko) * 2021-10-26 2023-05-03 사회복지법인 삼성생명공익재단 miRNA를 포함하는 대장암의 치료 및 전이 억제용 조성물 및 이의 용도
CN116735874B (zh) * 2022-03-11 2025-09-23 上海市免疫学研究所 结直肠癌肿瘤边界细胞亚群标志物组合及其应用
US20260043086A1 (en) * 2022-08-06 2026-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarker in avastin in colon cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172987A1 (en) 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
GB2339200B (en) 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO2000024940A1 (en) 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
EP0999016B1 (en) * 1998-11-06 2001-07-11 Temco S. R. L. Cutter for cross cutting of webs
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
EP1274463A2 (en) 1999-12-10 2003-01-15 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
US7029677B2 (en) * 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
EP1274865B1 (en) 2000-04-06 2007-02-14 Epigenomics AG Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis
WO2005000087A2 (en) 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
US20030166064A1 (en) 2000-08-03 2003-09-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CA2417866A1 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020110832A1 (en) 2000-08-03 2002-08-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030077568A1 (en) 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
US7105293B2 (en) 2000-09-19 2006-09-12 Whitehead Institute For Biomedical Research Genetic markers for tumors
WO2002058534A2 (en) 2000-11-20 2002-08-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
AU2002251844A1 (en) * 2001-02-02 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020197633A1 (en) * 2001-05-09 2002-12-26 Jones Brian C. Evaluation of ultraviolet radiation damage to skin using new gene markers, methods and compositions related thereto
US20030148314A1 (en) * 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030225526A1 (en) 2001-11-14 2003-12-04 Golub Todd R. Molecular cancer diagnosis using tumor gene expression signature
AU2002357747A1 (en) * 2001-12-10 2003-06-23 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
JP2005523688A (ja) 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
US7955800B2 (en) 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
US20040053317A1 (en) 2002-09-10 2004-03-18 Sidney Kimmel Cancer Center Gene segregation and biological sample classification methods
JP2006515318A (ja) 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
CA2516553C (en) 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
US20050014165A1 (en) 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
CA2533803A1 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
EP1756301A4 (en) 2004-04-16 2008-01-23 Univ Monash METHOD FOR MONITORING THE PROGRESS OF A CANCER DISEASE
US20080032293A1 (en) 2004-07-15 2008-02-07 The University Of North Carolina At Chapel Hill Housekeeping Genes And Methods For Identifying Same
US20060183893A1 (en) 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
WO2007070621A2 (en) 2005-12-13 2007-06-21 Children's Medical Center Corporation Prognosis indicators for solid human tumors
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
NZ593226A (en) * 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2007112330A2 (en) 2006-03-24 2007-10-04 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of colon cancer
US20090258795A1 (en) 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009114836A1 (en) 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy

Also Published As

Publication number Publication date
JP2013223503A (ja) 2013-10-31
NZ569788A (en) 2011-08-26
EP2412821B1 (en) 2014-09-17
JP5486718B2 (ja) 2014-05-07
US8367345B2 (en) 2013-02-05
JP2013226151A (ja) 2013-11-07
EP2377950A1 (en) 2011-10-19
US8198024B2 (en) 2012-06-12
JP2013176398A (ja) 2013-09-09
EP2412821A1 (en) 2012-02-01
EP2412824A1 (en) 2012-02-01
AU2007204826B2 (en) 2013-01-10
EP2377950B1 (en) 2014-09-17
NO20083461L (no) 2008-10-10
US20110097759A1 (en) 2011-04-28
NZ593229A (en) 2012-10-26
EP2412824B1 (en) 2014-10-08
US8153379B2 (en) 2012-04-10
JP2013074894A (ja) 2013-04-25
EP2412822A1 (en) 2012-02-01
EP2412823A1 (en) 2012-02-01
CA2636984A1 (en) 2007-07-19
JP5486717B2 (ja) 2014-05-07
NZ593225A (en) 2012-10-26
US7695913B2 (en) 2010-04-13
US8153378B2 (en) 2012-04-10
EP1974058A2 (en) 2008-10-01
JP5486720B2 (ja) 2014-05-07
JP5486664B2 (ja) 2014-05-07
US20110039272A1 (en) 2011-02-17
US8026060B2 (en) 2011-09-27
MX2008008973A (es) 2008-11-26
US20110111421A1 (en) 2011-05-12
NZ593226A (en) 2012-10-26
EP2400036A1 (en) 2011-12-28
JP2013226150A (ja) 2013-11-07
JP2009523028A (ja) 2009-06-18
AU2007204826A1 (en) 2007-07-19
NZ593227A (en) 2012-10-26
US8153380B2 (en) 2012-04-10
EP1974058B1 (en) 2014-06-11
DK1974058T3 (da) 2014-09-01
WO2007082099A2 (en) 2007-07-19
HK1120089A1 (en) 2009-03-20
BRPI0706511A2 (pt) 2011-03-29
US20110039270A1 (en) 2011-02-17
IL192794A0 (en) 2009-02-11
EP2412820A1 (en) 2012-02-01
US20130102492A1 (en) 2013-04-25
US20090291434A1 (en) 2009-11-26
US8029995B2 (en) 2011-10-04
US20100190173A1 (en) 2010-07-29
NZ593228A (en) 2012-10-26
US20110039271A1 (en) 2011-02-17
EP2407553A1 (en) 2012-01-18
US20110039269A1 (en) 2011-02-17
JP5486719B2 (ja) 2014-05-07
ES2491222T3 (es) 2014-09-05
IL192794A (en) 2013-07-31
JP2013215201A (ja) 2013-10-24
US20120171688A1 (en) 2012-07-05
WO2007082099A3 (en) 2008-01-17
US8273537B2 (en) 2012-09-25
KR20090003178A (ko) 2009-01-09
NZ593224A (en) 2012-10-26
EP2412823B1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
JP5297202B2 (ja) 結腸直腸癌の予後のための遺伝子発現マーカー
JP6246845B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP6351112B2 (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP4680898B2 (ja) 癌再発の可能性の予測
ES3027507T3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP7301798B2 (ja) 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
WO2008115419A2 (en) Gene expression markers for prediction of patient response to chemotherapy
WO2009114836A1 (en) Gene expression markers for prediction of patient response to chemotherapy
EP3556867A1 (en) Methods to predict clinical outcome of cancer
JP2012525159A (ja) 結腸直腸癌の再発および化学療法に対する応答の可能性における遺伝子発現プロファイルアルゴリズムおよび試験
EP2191020A2 (en) Gene expression markers of recurrence risk in cancer patients after chemotherapy
CN101400804B (zh) 用于结肠直肠癌预后的基因表达标志物
WO2013130465A2 (en) Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
AU2015202116B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK40014990A (en) Methods to predict clinical outcome of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090501

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130614

R150 Certificate of patent or registration of utility model

Ref document number: 5297202

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250